David Seaton, MD
Family Medicine · Somerville, TNNPI 1487748745
Payments from drug & device makers
Across 362 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$875
- GSK$824
- AstraZeneca$820
- Lilly USA, LLC$584
- Boehringer Ingelheim$275
- plus $3K from 30 others
What the payments were for
- Speaking & faculty fees$82512%
- Food & beverage$6,23887%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $1,216 |
| Novo Nordisk | 43 | $875 |
| GSK | 70 | $824 |
| AstraZeneca | 43 | $820 |
| Lilly USA, LLC | 38 | $584 |
| Boehringer Ingelheim | 16 | $275 |
| Astellas Pharma US Inc | 7 | $256 |
| Pfizer | 16 | $254 |
| Otsuka America Pharmaceutical, Inc. | 9 | $216 |
| Abbott | 9 | $198 |
| Bayer | 10 | $180 |
| Amarin Pharma, Inc. | 10 | $178 |
| Johnson & Johnson | 9 | $142 |
| Almatica Pharma LLC | 1 | $136 |
| Nestle Healthcare Nutrition Inc. | 7 | $118 |
| Amgen(2 entities) | 6 | $110 |
| Merck | 7 | $97 |
| Lundbeck LLC | 5 | $92 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $87 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $64 |
| Mylan Specialty L.p. | 4 | $63 |
| Exact Sciences | 3 | $49 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
| Seqirus USA Inc | 1 | $27 |
| Boston Scientific | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Insulet Corporation | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Athena Bioscience, LLC | 1 | $19 |
| Apria Healthcare LLC | 1 | $19 |
| Novartis | 1 | $18 |
| Ardelyx, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,163 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 435 | $518,987 |
| OzempicSemaglutide | 277 | $287,512 |
| EliquisApixaban | 389 | $213,982 |
| FarxigaDapagliflozin Propanediol | 192 | $174,344 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 215 | $156,465 |
| JardianceEmpagliflozin | 163 | $137,299 |
| TrulicityDulaglutide | 86 | $104,956 |
| RybelsusSemaglutide | 79 | $99,494 |
| JanuviaSitagliptin Phosphate | 119 | $71,064 |
| LinzessLinaclotide | 61 | $59,870 |
| XareltoRivaroxaban | 85 | $57,574 |
| EntrestoSacubitril/Valsartan | 53 | $53,916 |
| VraylarCariprazine Hcl | 26 | $37,280 |
| MyrbetriqMirabegron | 46 | $33,289 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 98 | $30,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $584 | $623,943521 claims |
| Novo NordiskOzempic, Rybelsus | $875 | $387,006356 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix, Anoro Ellipta, Breo Ellipta | $824 | $240,060462 claims |
| PfizerEliquis | $254 | $213,982389 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $820 | $207,656239 claims |
| Boehringer IngelheimJardiance | $275 | $137,299163 claims |
| AbbVieLinzess, Vraylar, Qulipta | $1,216 | $109,58199 claims |
| MerckJanuvia, Lagevrio (Eua), Belsomra | $97 | $103,248169 claims |
| Johnson & JohnsonXarelto, Invokana | $142 | $72,204102 claims |
| NovartisEntresto | $18 | $53,91653 claims |
| Astellas Pharma US IncMyrbetriq | $256 | $33,28946 claims |
| Aimmune Therapeutics, Inc.Zenpep | $33 | $17,43911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Somerville
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.